November 21, 2023 — AccurKardia, an ECG-led diagnostics software company, announced a multi-year agreement with Lucem Health, a leading provider of clinical AI solutions. The partnership paves the way for AccurKardia to integrate its FDA-Cleared ECG Interpretation Software Platform, AcurrECG Analysis System (“AccurECG”), into Lucem Health Reveal, a family of solutions that identify patients who may be at higher risk of severe or chronic diseases.
AccurKardia’s AccurECG is a cloud-based, device-agnostic, fully automated ECG interpretation software platform that can detect up to 13 arrhythmias. This technology assists cardiac monitoring companies in analyzing ECGs recorded from a wide array of inputs from wet electrode devices.
“Our software helps clinicians review ECGs more efficiently and enables prompt treatment of patients, with key cardiovascular insights delivered in minutes. This partnership with Lucem Health allows us to bring the power of our technology to Lucem Health’s clinical AI solution,” said Juan C. Jiménez, CEO of AccurKardia. “This is an important step in our mission to improve patients’ outcomes and save lives at scale.”
“Lucem Health’s Reveal solutions provide a unique way to identify patient health risks hiding in plain sight. Our partnership with AccurKardia enables us to extend Reveal’s benefits to cardiovascular diseases,” said Jeremy E. Pierotti, General Manager of Solutions at Lucem Health. “We’re committed to providing clinicians with the most advanced tools for early diagnosis and intervention of chronic diseases. Later this year, we’ll announce our first product incorporating AccurKardia’s FDA-cleared technology."
For more information: www.accurkardia.com
January 15, 2026 
